FBRX

Business Context and Reporting Period

Company: Forte Biosciences, Inc. (FBRX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Forte is a clinical-stage biopharmaceutical company focused on autoimmune diseases. Its lead product candidate, FB102 (an anti-CD122 monoclonal antibody), is in Phase 2 trials for celiac disease and Phase 1b trials for vitiligo and alopecia areata. The company has no approved products and has not generated product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased R&D Spend: Research and development expenses increased by approximately $21.5 million (101%) compared to the prior year period. This was driven by manufacturing and clinical expenses for the Phase 2 celiac trial and Phase 1b trials for vitiligo and alopecia areata, as well as increased personnel costs.
• Decreased G&A Expenses: General and administrative expenses decreased by approximately $2.2 million. This reduction was primarily due to $4.8 million in legal settlement payments received from insurance carriers (Palms and Wesco) related to a prior directors' and officers' liability dispute, partially offset by higher stock-based compensation.
• Capital Raise: In April 2026, the company completed a public offering raising gross proceeds of $172.5 million (including the underwriters' option), significantly increasing liquidity compared to the prior year.
• Investing Activities: Net cash used in investing activities was $147.8 million, primarily due to the purchase of U.S. Treasury bills using proceeds from the 2026 offering. In the prior year, investing activities provided cash due to redemptions of short-term investments.

Outlook, Risks, and Unusual Items

• Pending Acquisition: On July 26, 2026 (subsequent to the period end), Forte entered into a definitive agreement to be acquired by argenx BV. The transaction involves a tender offer at $77.00 per share in cash. The deal is subject to customary closing conditions, including a minimum tender threshold and regulatory approvals. A termination fee of $65 million is payable by Forte under specified circumstances.
• Clinical Milestones: Topline data for the Phase 2 celiac study and Phase 1b alopecia areata study are expected in the second half of 2026. Positive topline data for the Phase 1b vitiligo trial was announced in July 2026.
• Liquidity: Management believes existing cash and investments ($198.5 million) are sufficient to fund operations for at least 12 months from the filing date. However, the company expects to incur significant losses in the foreseeable future and will require additional funding to complete development and commercialization.
• Risks: Key risks include the uncertainty of the argenx merger completion, the failure of FB102 to demonstrate efficacy in later-stage trials, reliance on third-party manufacturers, and potential intellectual property disputes.

Investor Verification Checklist

• Merger Status: Verify the current status of the argenx tender offer and whether the minimum tender condition has been met.
• Clinical Data: Monitor the release of topline data for the Phase 2 celiac and Phase 1b alopecia areata trials expected in late 2026.
• Burn Rate: Assess the sustainability of the current cash balance ($198.5 million) against the accelerating R&D spend ($42.8M for six months) to determine if further dilution is required before the merger closes.
• Legal Settlements: Confirm the finalization of the insurance dispute settlements and ensure no further liabilities remain regarding the underlying action.
• Stock-Based Compensation: Review the $47.8 million in unrecognized stock-based compensation expense, which will impact future earnings.